ArticleSubstance abuse treatment, prevention, and policy2020
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Article in Substance abuse treatment, prevention, and policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Physician Reluctance to Intervene in Addiction: A Systematic Review.JAMA network open · 2024Pooled it
- Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.Psychiatric services (Washington, D.C.) · 2023Trial
- Feasibility of Implementing a Pharmacist-Integrated Collaborative Model for Opioid Use Disorder: A Nonrandomized Clinical Trial.Journal of general internal medicine · 2026Article
- State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients.JAMA health forum · 2026Article
- "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs.Addiction science & clinical practice · 2025Article
- Experiences of Team Collaboration in Primary Care-Based Delivery of Opioid Use Disorder Treatment.The journal of behavioral health services & research · 2025Article
- Implementing buprenorphine for opioid use disorder in veterans health administration primary care: a qualitative analysis.Addiction science & clinical practice · 2025Article
- Barriers and facilitators to prescribing buprenorphine for treating opioid use disorder among emergency department and other practice setting physicians.AIMS public health · 2025Article
- Understanding MAT access in the context of unused MAT capacity in the United States: when increasing rural MAT capacity is not enough.Substance abuse treatment, prevention, and policy · 2024Observational
- Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors.Journal of general internal medicine · 2024Article
- State drug caps associated with fewer Medicaid-covered prescriptions for opioid use disorder, 2017-2022.Health affairs scholar · 2024Article
- U.S. Healthcare Workers' Perspective of Outpatient Provision of Methadone: A Scoping Review.Substance use & addiction journal · 2024Article
- Article
- Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations.Addiction science & clinical practice · 2024Article
- Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review.Frontiers in public health · 2024Review
- Mobilizing Primary Care Against the Opioid Crisis in the Post X-Waiver Era.Journal of general internal medicine · 2023Article
- Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.Annals of medicine · 2023Article
- Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.JAMA health forum · 2023Article
- Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.The American journal of drug and alcohol abuse · 2023Article
- Integrating Opioid Use Disorder Treatment Into Primary Care Settings.JAMA network open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundEvidence demonstrates that medications for treating opioid use disorder (MOUD) -namely buprenorphine, methadone, and extended-release naltrexone-are effective at treating opioid use disorder (OUD) and reducing associated harms. However, MOUDs are heavily underutilized, largely due to the under-supply of providers trained and willing to prescribe the medications.
methodsTo understand comparative beliefs about MOUD and barriers to MOUD, we conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine. Focus group results were analyzed using thematic analysis. Survey results were analyzed using descriptive and inferential statistical methods.
resultsStudy findings suggest that physicians have higher perceptions of efficacy for methadone and buprenorphine than for extended-release naltrexone, including for patients with co-occurring mental health disorders. Insurance obstacles, such as prior authorization requirements, were the most commonly cited barrier to prescribing buprenorphine and extended-release naltrexone. Regulatory barriers, such as the training required to obtain a federal waiver to prescribe buprenorphine, were not considered significant barriers by many physicians to prescribing buprenorphine and naltrexone in office-based settings. Nor did physicians perceive diversion to be a prominent barrier to prescribing buprenorphine. In focus groups, physicians identified financial, logistical, and workforce barriers-such as a lack of addiction treatment specialists-as additional barriers to prescribing medications to treat OUD.
conclusionsAdditional education is needed for physicians regarding the comparative efficacy of different OUD medications. Governmental policies should mandate full insurance coverage of and prohibit prior authorization requirements for OUD medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.